


How do I get more information?

To find out more, please contact the study team using the information provided here.

Study participation is voluntary. By contacting us, you are under no obligation to take part in the study.



Patient Information

This brochure contains information about the CHALLENGE-MIG Study for participants with episodic migraine. This information should help you decide whether you, or someone you know, may want to take part in the study.

What is a clinical research study?

A clinical research study is a medical study that helps to answer important questions about investigational medications or seeks to find out more information about approved medications.

The CHALLENGE-MIG Study is a clinical research study comparing 2 approved medications for the prevention of episodic migraine. Currently, there is a gap in the information about migraine prevention treatment that is needed by patients with episodic migraine and their healthcare providers. This study will gather more information to help patients and their healthcare providers make more informed treatment decisions.


Clinical research studies should include all kinds of people as certain conditions and medications may affect people differently based on their age, sex, gender, and race/ethnicity.



Deciding to take part in a clinical research study is an important decision. If you have any questions, you can contact the study team using the information provided on the back of this brochure.

About the CHALLENGE-MIG Study

This study will look at how well an approved medication for migraine works in adults with episodic migraine, compared with another approved medication. The study will also look at how safe the 2 medications are.



Why is this study important?

CGRP antagonists are a type of medication that the US Food and Drug Administration (FDA) has approved for the treatment of migraine. CGRP antagonists are administered as an injection under the skin (subcutaneously). They have also been made available recently as oral medications that can be taken by mouth.

This will be the first study to compare 2 different approved CGRP antagonists for the prevention of episodic migraine: an injectable medication and an oral medication. The results of this study may help healthcare providers and people with episodic migraine make more informed decisions about treatment in the future.

What will the CHALLENGE-MIG Study involve?

If you take part, you will be in this study for up to 6 months. You will have an equal chance to receive either the injectable medication or the oral medication. You will also receive a placebo, either as an injection or orally.

A placebo looks like the approved medication (either the injectable medication or oral medication) but contains no active ingredient. The injectable medication, oral medication, and placebo are together called the “study medication.”



4
visits



2
phone calls

You will need to:

- attend 4 visits to the study center and have 2 phone calls
- take the study medication
- use an electronic diary (eDiary) every day



The study is made up of 3 parts.

Screening period (up to 1 month)



- You will visit the study center to see if you are eligible for the study and whether you want to take part.

Baseline period (about 1 month)



- You will visit the study center again to see if you are still eligible for the study.
- You will start to use an eDiary every day to answer questions about your headaches.

Study treatment period (about 3 months)




- If you are eligible for the study, you will enter the study treatment period. During this period, you will:
 - ▲ visit the study center 2 times and will have 2 phone calls for study assessments
 - ▲ continue to use your eDiary every day
 - ▲ receive the study medication
 - At your first visit to the study center during this period, you will receive 2 injections and 1 tablet by mouth. Thereafter, you will take 1 injection each month, for 2 months at home. You will also take 1 tablet by mouth every other day, for 3 months at home.

Who can take part?

You, or someone you know, may be able to take part if you/they:

- are 18–65 years of age
- have been diagnosed with migraine
- have a history of migraine headaches of at least 1 year



18-65
years of age



What else do I need to consider?

- The study team will explain the possible benefits and risks of the study.
- You do not have to take part in the study if you do not want to.
- If you choose to take part in the study, you can stop participating at any time.
- You will not be paid to take part in this study, but you may be reimbursed for reasonable travel costs during your participation.
- The study medication and all study-related tests will be provided at no cost to you.
- A team of doctors and nurses will monitor your health carefully during the study.
- The study has been approved by an Institutional Review Board (IRB), which protects the rights, safety, and well-being of the participants.